Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CHRS Coherus Oncology	$1.04 +3.6%	$0.85	$0.66 ▼ $2.43	$119.99M	0.89	1.69 million shs	726,910 shs
CMPX Compass Therapeutics	$3.00 -3.2%	$2.78	$1.15 ▼ $4.08	$414.85M	1.49	1.42 million shs	1.31 million shs
CYRX CryoPort	$8.89 -2.1%	$7.36	$4.58 ▼ $9.66	$445.59M	1.88	537,806 shs	242,705 shs
MBX MBX Biosciences	$13.20 +1.9%	$12.11	$4.81 ▼ $27.50	$440.25M	N/A	326,805 shs	229,935 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CHRS Coherus Oncology	+9.07%	+9.10%	+5.19%	+30.08%	-30.63%
CMPX Compass Therapeutics	-2.21%	+6.53%	+6.16%	+53.47%	+158.33%
CYRX CryoPort	+6.95%	+3.77%	+21.07%	+34.92%	+10.73%
MBX MBX Biosciences	+3.35%	+10.97%	-6.63%	+21.60%	+1,294,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CHRS Coherus Oncology	4.3001 of 5 stars	3.3	0.0	4.5	1.6	2.5	2.5
CMPX Compass Therapeutics	2.8845 of 5 stars	3.6	1.0	0.0	2.8	5.0	0.0
CYRX CryoPort	3.5683 of 5 stars	4.5	1.0	0.0	2.6	2.5	1.3
MBX MBX Biosciences	2.5424 of 5 stars	3.5	0.0	0.0	3.0	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CHRS Coherus Oncology	2.67	Moderate Buy	$4.68	352.50% Upside
CMPX Compass Therapeutics	3.10	Buy	$12.89	329.63% Upside
CYRX CryoPort	3.00	Buy	$12.00	35.03% Upside
MBX MBX Biosciences	3.00	Buy	$37.63	185.10% Upside

Current Analyst Ratings Breakdown

Latest CHRS, CYRX, MBX, and CMPX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
8/6/2025	CYRX CryoPort	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/6/2025	CYRX CryoPort	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Weight ➝ Overweight	$15.00
8/6/2025	CYRX CryoPort	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$16.00
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/22/2025	CYRX CryoPort	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$13.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/7/2025	CYRX CryoPort	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $10.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CHRS Coherus Oncology	$266.96M	0.45	$0.33 per share	3.14	$1.03 per share	1.00
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	$0.67 per share	N/A
CYRX CryoPort	$228.38M	1.95	N/A	N/A	$7.44 per share	1.19
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CHRS Coherus Oncology	$28.51M	$1.55	0.67	N/A	N/A	125.90%	N/A	-34.85%	N/A
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	N/A
CYRX CryoPort	-$114.76M	$1.33	6.68	N/A	N/A	37.21%	-10.48%	-5.56%	N/A
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest CHRS, CYRX, MBX, and CMPX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/5/2025	Q2 2025	CYRX CryoPort	-$0.20	-$0.29	-$0.09	$2.05	$41.74 million	$45.45 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CHRS Coherus Oncology	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CYRX CryoPort	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CHRS Coherus Oncology	0.31	1.44	1.78
CMPX Compass Therapeutics	N/A	7.66	8.33
CYRX CryoPort	0.51	5.56	5.24
MBX MBX Biosciences	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CHRS Coherus Oncology	72.82%
CMPX Compass Therapeutics	68.43%
CYRX CryoPort	92.90%
MBX MBX Biosciences	N/A

Insider Ownership

Company	Insider Ownership
CHRS Coherus Oncology	8.08%
CMPX Compass Therapeutics	29.80%
CYRX CryoPort	10.00%
MBX MBX Biosciences	52.19%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CHRS Coherus Oncology	330	115.93 million	106.57 million	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CYRX CryoPort	1,186	50.14 million	45.12 million	Optionable
MBX MBX Biosciences	36	33.59 million	N/A	N/A

CHRS, CYRX, MBX, and CMPX Headlines

Recent News About These Companies

A Glimpse of MBX Biosciences's Earnings Potential

4 hours ago | benzinga.com

MBX Biosciences, Inc. (NYSE:MBX) Given Consensus Recommendation of "Buy" by Analysts

August 14 at 2:27 AM | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Receives Consensus Recommendation of "Buy" from Brokerages

August 13 at 2:29 AM | americanbankingnews.com

MBX Biosciences Reports Progress and Financial Stability

August 11 at 12:50 AM | tipranks.com

MBX Biosciences (NYSE:MBX) Earns Outperform Rating from Analysts at Mizuho

August 8, 2025 | americanbankingnews.com

MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

August 7, 2025 | globenewswire.com

MBX Biosciences (NYSE:MBX) Coverage Initiated at Mizuho

August 6, 2025 | marketbeat.com

Mizuho Initiates Coverage of MBX Biosciences (MBX) with Outperform Recommendation

August 5, 2025 | msn.com

TD Asset Management Inc Raises Stock Holdings in MBX Biosciences, Inc. (NYSE:MBX)

August 5, 2025 | marketbeat.com

MBX Biosciences Inc. (MBX) Stock Price Today - WSJ

August 2, 2025 | wsj.com

MBX Biosciences (NYSE:MBX) Shares Up 15.7% - What's Next?

July 26, 2025 | marketbeat.com

MBX Biosciences, Inc. (NYSE:MBX) Receives Average Rating of "Buy" from Analysts

July 19, 2025 | marketbeat.com

Oppenheimer Initiates Coverage of MBX Biosciences (MBX) with Outperform Recommendation

July 17, 2025 | msn.com

Oppenheimer Initiates Coverage on MBX Biosciences (NYSE:MBX)

July 16, 2025 | marketbeat.com

MBX Biosciences Inc Executives - Morningstar

June 25, 2025 | morningstar.comM

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development - Morningstar

June 24, 2025 | morningstar.comM

MBX Biosciences Inc Chart - Morningstar

June 24, 2025 | morningstar.comM

MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development

June 23, 2025 | globenewswire.com

MBX Biosciences Submits IND for Obesity Treatment

June 16, 2025 | tipranks.com

MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity

June 16, 2025 | globenewswire.com

MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions

June 10, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CHRS, CYRX, MBX, and CMPX Company Descriptions

Coherus Oncology NASDAQ:CHRS

$1.03 +0.04 (+3.60%)

As of 03:00 PM Eastern

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Compass Therapeutics NASDAQ:CMPX

$3.00 -0.10 (-3.23%)

As of 03:00 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

CryoPort NASDAQ:CYRX

$8.89 -0.19 (-2.13%)

As of 03:01 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

MBX Biosciences NYSE:MBX

$13.20 +0.25 (+1.91%)

As of 03:01 PM Eastern

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time